Preference for diagnostic laboratories for uterine cancer diagnostic testing being driven by their efficient sample handling and consistent test results.

ROCKVILLE, MD, UNITED STATES, July 4, 2024 /EINPresswire.com/ -- According to a recent research report published by Fact.MR, the global uterine cancer diagnostic testing market is set to reach US$ 3.23 billion in 2024 and advance thereafter at 7.7% CAGR from 2024 to 2034.

Diagnostic testing for uterine cancer includes blood tests, biopsies, and ultrasound scans. Ultrasound scanning tests create images of the uterus and ovaries by using sound waves. As uterine cancer cases rise globally, there is a growing need for diagnostic testing to detect and treat the disease early. Advancements in genetic testing, biomarker identification, and imaging techniques (MRI and ultrasound) have improved the accuracy and efficacy of uterine cancer diagnosis.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10220

Rising incidence of uterine cancer and the growing global aging population are projected to drive up demand for diagnostic testing among older women over the forecast period. Public health campaigns and initiatives that raise awareness of women's health issues, especially uterine cancer, and encourage early detection through routine screenings are expected to contribute to the growth of the uterine cancer diagnostic testing market.

Key Takeaways from Market Study

The global market for uterine cancer diagnostic testing is on a growth trajectory, projected to expand at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2034. By the end of this period, the market size is expected to reach an impressive US$ 6.76 billion. In the United States, the market is anticipated to hit a value of US$ 1.35 billion in 2024. Meanwhile, Chile is set to capture a substantial 38.6% market share in Latin America for the same year. This growth indicates significant advancements in diagnostic technologies and increased awareness and screening efforts for uterine cancer across these regions.

In Brazil, revenue from uterine cancer diagnostic testing is projected to reach US$ 98.37 million by the end of 2034, reflecting the region's growing emphasis on women's health. The North American market, including the U.S., is forecasted to grow at a CAGR of 5.6% from 2024 to 2034, underlining the steady demand for diagnostic services in the region. Hospitals, as a crucial end-user segment, are calculated to generate revenue of US$ 1.21 billion by 2034. These projections underscore the critical role of healthcare institutions in driving market expansion and highlight the increasing global prioritization of early cancer detection and treatment.

“Continuous advancements in genetic testing, biomarker identification, and imaging technologies are benefitting providers of uterine cancer diagnostic testing,” says a Fact.MR analyst.

Availability of Highly Qualified Medical Specialists Prompting More Patients to Favor Diagnostic Laboratories for Uterine Cancer Diagnosis

Advanced technologies and specialized equipment required for various diagnostic tests, including uterine cancer tests, are often found in diagnostic laboratories. They serve as focal points for the examination of samples taken from different medical facilities (clinics, hospitals, etc.).

Medical technologists, pathologists, and cytotechnologists are among the skilled healthcare professionals who work in diagnostic laboratories and have specialized knowledge in accurately interpreting diagnostic tests. Accredited laboratories adhere to strict quality standards, which ensure reliable and consistent test results.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=10220

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the uterine cancer diagnostic testing market for 2018 to 2023 and forecast statistics for 2024 to 2034.

The study divulges the uterine cancer diagnostic testing market based on cancer type (endometrial carcinoma, uterine sarcoma), diagnostic test (ultrasound scanning, biopsy, blood test), and end user (hospitals, ambulatory surgical centers, cancer research centers, specialized clinics, diagnostic laboratories), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Explore More Related Studies Published by Fact.MR Research:

Ovarian Cancer Diagnostics Market: This global ovarian cancer diagnostics market analysis by Fact.MR predicts the industry to expand at a robust CAGR of 7% from 2021 to 2031.

Liver Cancer Diagnostics Market: The global liver cancer diagnostics market reached a valuation of around US$ 11.73 Bn in 2022 and is slated to accelerate at a CAGR of 8.2% to top US$ 26 Bn by 2032. This noteworthy jump in market size is because of growing investments in research programs in regions like North America & Europe.

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com

S. N. Jha
Fact.MR
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.